Stanford spinout Bolt Biotherapeutics has raised more than twice as much as originally planned in an offering that also provided exits for corporates Pfizer, Novo and Fan Fung.

Bolt Biotherapeutics, a US-based oncology therapy spinout of Stanford University, went public on Friday after issuing 11.5 million shares priced at $20 to raise $230m in proceeds. Shares surged more than 60% to close at $32.15 on the first day of trading on the Nasdaq Global Select Market, where the spinout is now listed under…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.